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Abstract 
Background: CAT25 (T25mononucleotide repeat of the Caspase 2 gene), is a 
promising DNA marker for detecting microsatellite instability (MSI) in colorectal 
cancer. CAT25 has the potential to be incorporated into the Bethesda panel, a 
commonly used panel of DNA microsatellites, or replace it in its entirety. We aimed 
to develop and validate a high-resolution melting-PCR (HRM-PCR) method for 
CAT25 instability detection in clinical samples and study its allelic variation in our 
population. 
Methods: The instability of CAT25, BAT25 (a poly(A) tract occurring in the c‐kit 
gene) and BAT26 (a poly(A) tract localized in the hMSH2 gene) microsatellites was 
assessed in DNA from tumour and peripheral blood obtained from 110 patients with 
colorectal cancer using HRM-PCR and capillary electrophoresis. 
Immunohistochemistry (IHC) staining for MSH2, MSH6, MLH1, and PMS2 enzymes 
was performed on tumours with high MSI. Allelic size variation of CAT25 was 
analyzed on periph ral blood DNA from 208 healthy volunteers. 
Results: The HRM-PCR for CAT25 was validated in clinical samples. CAT25 
showed a tight range of 64-66 base pairs. Of 110 tumours, 11 had high MSI, later 
confirmed by IHC. CAT25 defined MSI alone and when used together with BAT25 
and BAT26. CAT25 results provided 100% predictive values and p<0.0001 to 
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Conclusions: We developed and validated a new HRM-PCR assay to detect CAT25 
instability. Our findings showed a limited allelic size variation of CAT25 in the 
population and highlight CAT25 as a promising marker for MSI analysis.  
 
Introduction 
Microsatellites are sequences of repetitive DNA units (1 to 7 base pairs), and 
are likely sites of replication errors due to a failure of the DNA mismatch repair 
(MMR) system during DNA replication. These errors can be caused by either 
mutations or epigenetic modifications in the MMR genes resulting in microsatellite 
instability (MSI). The presence of MSI is indicated by the different number of base 
pairs of microsatellites from tumour DNA, with respect to the number of base pairs 
present in the normal DNA as can be found in peripheral blood cells. MSI screening 
is a well-established assay for defining Lynch syndrome (1). Individuals with this 
condition have a 50-70% lifetime risk of developing colorectal cancer and 40-60% of 
them are at risk of developing endometrial cancer and other malignancies (2). MSI 
status has also been proposed as a prognostic factor related to survival and is 
postulated as a predictive factor of response to the adjuvant therapy for patients with 
colorectal cancer (3,4). Recent data have shown the importance of MSI testing for 
the selection of patients for immunotherapy using anti-PD-1/PD-L1 therapy (5). 
The Bethesda panel is frequently used to assess the presence of MSI in 
colorectal cancer. The panel consists of two mononucleotides, BAT25 (a poly(A) 
tract occurring in c‐kit) and BAT26 (a poly(A) tract localized in hMSH2) along with 
three dinucleotide markers (D17S250, D5S346, and D2S123) (6). However, this 
panel has limitations, since dinucleotide markers are less sensitive and specific for 









2019-0255 approved by ADB 10th February 2020 
4 
 
this deficiency, only the use of mononucleotide markers was suggested for MSI 
testing (7). Furthermore, the use of mononucleotide microsatellites with limited allelic 
size variation could potentially avoid testing the corresponding normal DNA present 
in  peripheral blood samples, often used as reference for MSI analysis (8)(9). In line 
with this, CAT25, a mononucleotide microsatellite with 25 repetitions of thymine 
located in the 3’untranslated region of the CASP2 gene has assessed for MSI testing 
(10). Moreover, different groups have demonstrated the usefulness of CAT25 in 
terms of clinical efficacy, suggesting that it is comparable to all the five 
microsatellites proposed in the Bethesda panel (10–13). The findings and needs 
described above highlight the importance of further studies of CAT25 in colorectal 
cancer. Here, we developed and validated a new HRM-PCR technique for CAT25 
instability detection, which is usually performed using capillary electrophoresis 
technique. The HRM-PCR technique is a simpler and faster technique than capillary 
electrophoresis and has no problems with stutter bands as does capillary 
electrophoresis (14,15). Another advantage is that in contrast to capillary 
electrophoresis, HRM-PCR works in a closed-system environment, which also 
reduces contamination risks with amplicons (15)(16).  
We present data supporting the use of CAT25 MSI testing, using colorectal 
tumours as a model, both alone and together with BAT25 and BAT26. 
 
Materials and methods 
One hundred and ten individuals (43 women / 67 men) with colorectal 
adenocarcinoma diagnosed by histopathological analysis and treated in our hospital 
were studied. The mean age was 66 years (range: 30-89). The number and tumour 
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in rectosigmoid and 20 in the rectum. The cancers were classified according to The 
International Union Against Cancer (UICC)/American Joint Committee on Cancer 
(AJCC) guidelines as follows: 19, 33, 34, and 19 tumours recorded as stage I, II, III 
and IV respectively. Five tumours could not be classified by their stage. At diagnosis, 
27 patients presented with metastases and in several of them, a carcinogenic 
involvement of more than one location was found. The number and anatomical sites 
affected by metastases were: 21 livers, 4 lungs, 2 bladders, 3 peritonea, 1 omentum, 
and 1 bone tissue. Before colorectal tumour removal surgery, there were 3 patients 
with rectal cancer who received neoadjuvant therapy with radiotherapy and 
chemotherapy (leucovorin and 5-fluorouracil). After colorectal surgery, adjuvant 
therapy was administered to 51 patients according to medical criteria (leucovorin, 5-
fluorouracil, capecitabine, irinotecan, oxaliplatin, bevacizumab using one drug or a 
combination of them). The average overall survival at 60 months after colorectal 
surgery was 43 months.  
Five mL of peripheral blood and a piece of fresh tumour tissue were obtained from 
each patient. The CAT25 allelic pattern was determined using genomic DNA from 
peripheral blood  (2.5mL) of 208 (104 women / 104 men) healthy volunteers (17). 
The study was approved by the Ethics Committee of the Hospital Privado 
Universitario de Cordoba and a written informed consent was obtained from all 
individuals. 
Genomic DNA extraction was a follows. Genomic DNA from peripheral blood was 
extracted using MagNA Pure Compact Nucleic Acid Isolation Kit I following 
manufacturer’s instructions (Roche applied science, Mannheim, Germany). This was 
also used to obtain Genomic DNA from fresh-frozen tumours as previously were 
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digestion step (2 mg/mL overnight at 56ºC). Nucleic acid concentration was 
determined with an ultraviolet spectrophotometer (MaestroNano, MaestroGen Inc, 
Hsinchu City, Taiwan). 
HRM-PCR conditions were as follows. The novel SmallCAT25 primers (Forward; 5’-
CTTCCCAACTTCCCTGTTCTTT-3’ and Reverse; 5’-GGCGACAGAGCGAGACT-3’) 
were generated from GenBank accession number NM_032982 using PrimerQuest 
software (Integrated DNA Technologies, Coralville, USA) (19). These primers were 
created to generate a small amplicon (65bp) and to avoid Alu sequences as 
suggested before (13). The procedure was carried out following criteria for HRM-
PCR setting (20). The reactions were carried out on HRM-compatible instruments: 
Eco Real-time PCR system (ECO) (Illumina, San Diego, USA) for technique 
validation, and Rotor-Gene 6000 (RG) (Qiagen, Hilden, Germany) and LightCycler 
Z480 (Z480) (Roche applied science, Mannheim, Germany) for the robustness assay 
(only for CAT25 analysis). HRM-PCR was accomplished in a total reaction volume of 
10 µL containing: 0.2 µL of each SmallCAT25 primer (10 pmol/ µL), 5 µL of Kapa 
HRM Fast master mix 2x (Kapa Biosystems, Wilmington, USA) 1.2 µL  of MgCl2 25 
mM (Kapa Biosystems, Wilmington, USA), 1 µL of DNA template (25ng/ µL) and 2.4 
µL of water. The HRM-PCR cycling conditions were: 95°C for 3 minutes followed by 
42 cycles of 95°C for 5 seconds and 64°C for 30 seconds. Before HRM step, the 
products were heated to 95°C for 10 seconds and cooled to 40°C for 5 seconds. 
Data for HRM analysis were collected within the range of 65 to 95°C, rising at 
0.1°C/second (RG and ECO instruments) or 0.02°C/second with 25 
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Validation parameters. Validation parameters for CAT25 HRM-PCR analysis were 
performed according to the guidelines for molecular genetics techniques as 
previously published (21). 
Analytic sensibility and specificity determinations were as follows: measurements 
were calculated taking into consideration the capillary electrophoresis results. For 
evaluation of the template amount variation, DNA of Tumour 109/peripheral blood 
109 (from the same patient) were added in triplicate to the reaction at different 
concentrations (10 ng, 25 ng, 40 ng, and 80 ng). Additionally, we performed the 
HRM-PCR assay for CAT25 instability detection using DNA from 11 tumours with 
high MSI on three Real-time PCR instruments with HRM ability: ECO, RG, and Z480. 
Intra-run precision–repeatability: A single operator ran 10 replicates of the tumour 
DNA sample vs. 10 replicates of peripheral blood DNA from the same patient within 
the same run. These samples differed in one nucleotide length. 
Inter-run precision–reproducibility (inter-run precision) was determined with the same 
samples used for previous tests, a single operator repeated the procedure on three 
different days. The samples were run in triplicate. 
For HRM-PCR validation and testing of the allelic repeat pattern of CAT25, a 
fluorescent PCR-based assay followed by capillary electrophoresis analysis 
(ABI3730XL instrument, Applied Biosystems, Foster City, USA) was performed. To 
amplify the CAT25 marker, SmallCAT25 primers with the labelled (FAM) forward 
primer and the same cycling cited for HRM-PCR were used. Capillary 
electrophoresis assay was performed by Macrogen (Seoul, Korea). We used Peak 
Scanner Software 2 (Thermo Fisher Scientific, Waltham MA, USA) to estimate the 
amplicon size. Procedure time (approximate): 120 minutes. To amplify BAT25 and 









2019-0255 approved by ADB 10th February 2020 
8 
 
Forward primers were labelled with FAM (BAT25) and HEX (BAT26) fluorophores. 
Capillary electrophoresis analysis was performed following the same procedure as 
for CAT25. 
Immunohistochemistry was performed on 9 biopsy samples classified as high MSI. 
Samples were fixed in 10% pH 7 buffered formaldehyde before being embedded in 
paraffin, and then 5 microns sections were made from selected blocks. The primary 
antibodies used were: MSH2 (CELL MARQUE, clone 6219-1129); MSH6 (CELL 
MARQUE, clone 44); MLH1 (Ventana, clone M1) and PMS2 (Ventana, clone 
ERP3947). The technique was carried out on Benchmark GX - VENTANA platforms 
(Roche, applied science, Mannheim, Germany) and revealed with Optiview DAB 
Detection Kit (Roche, applied science, Mannheim, Germany) in all cases. For the 
markings of MLH1 and PMS2, Optiview Amplification Kit (Roche, applied science, 
Mannheim, Germany) was also used according to protocols suggested by the 
manufacturer. Subsequently, the slides with the samples were dehydrated and 
mounted for visualization and evaluation under an optical microscope. A sample was 
considered negative when no tumour cell nucleus with positive staining for the 
protein under study (MSH2, MSH6, MLH1 or PMS2) was observed. Positive staining 
from the proteins studied observed in the cell nuclei of infiltrating lymphocytes, 
stromal cells and normal mucosa was considered as positive internal controls. 
CAT25, BAT25 or BAT26 instability was considered when a different amplicon size 
for each marker by capillary electrophoresis analysis was found comparing tumour 
DNA vs. peripheral blood DNA of the same patient. In HRM-PCR analysis, CAT25, 
BAT25 and BAT26 instability was considered to be present when HRM curves 
(Normalized and Different plot) were discordant between the samples previously 
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Tumour samples were considered to have high MSI when at least two of three 
mononucleotide markers (BAT25, BAT26, CAT25) showed instability by capillary 
electrophoresis analysis (10,11,22). Predictive values and Fisher’s exact test were 
calculated using GraphPad Prism 5 for Windows (GraphPad Software, Inc, San 
Diego, CA). 
Results 
CAT25 amplification using SmallCAT25 primers. According to the procedure 
described in materials and methods, the HRM-PCR for CAT25 MSI analysis 
generated only one specific product with an adequate cycle threshold (CT) for HRM 
analysis (CT<30). The test reached 100% sensitivity and specificity for CAT25 since 
there was full concordance between the capillary electrophoresis and HRM-PCR 
results obtained with the analysis of 110 tumours and the paired peripheral blood 
from patients with colorectal cancer. 
Different amounts of DNA template from a high MSI tumour/PB ranging from 
10 to 80 ng/reaction were studied. The 10 to 40 ng/reaction range provided a better 
interpretation of HRM curves, so that 25 ng/reaction was chosen for the following 
runs to be performed (Figure 1 A, B). We found the same results for the 11 tumours 
with CAT25 instability in the three thermocyclers used. The reaction was 
reproducible in the intra-run precision–repeatability assay since the replicates 
grouped and melting profiles were equal for each sample in all 10 replicates (Figure 
1 C, D). In addition, there was no misinterpretation of HRM curves when the same 
procedure was performed on different days (Inter-run precision–reproducibility 
assay). 
CAT25, BAT25 and BAT26 instability and predictive values data is as follows. The 
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outcomes and made it possible to distinguish the differences in bp between the study 
samples (Figure 2). Taking into account the results of the three microsatellite 
markers studied, 11 of the 110 tumours analyzed were classified as high MSI. The 
instability of the microsatellites analyzed by capillary electrophoresis, demonstrated 
the base pair shift, which in all cases was shown as shortening the length of the 
markers. The averages and standard deviations of these shifts in base pairs for each 
marker can be visualized in Table 1. The altered tumours displayed shifted HRM 
curves vs. those generated by PB from the same patient (Figure 2). Eleven samples 
from 110 colorectal tumour tissue presented allelic variation for CAT25, showing 
100% positive predictive values (PPV) (95% CI, 71.5 to 100) and negative predictive 
values (NPV) (95% CI, 96.3  to 100) (p<0.001) for high MSI classification, using 
either HRM or capillary electrophoresis analysis. 
 Ten and 13 samples of the 110 cancers presented allelic variation for BAT25 
and BAT26, respectively. One false positive for MSI-high classification was obtained 
for both BAT25 (tumour from patient 82) and BAT26 (tumour from patient 107) 
(Table 1). These data showed PPV for MSI testing of 92% for both. Two and no false 
negative were obtained for BAT25 (tumours from patients 35 and 64) and BAT26, 
respectively (Table 1). They also displayed NPV of 98% and 100%, respectively.  
Allelic pattern analysis of CAT25. DNA samples from the healthy control group (n= 
208) and high MSI tumours (n= 11) were studied by capillary electrophoresis 
analysis using SmallCAT25 primers. This analysis showed a tight allelic range for 
CAT25: The control group data was mean [SD] 64.9 [0.55] bp, the patient data was 
60.3 [2.4] bp (p<0.01). 
One of 11 tumours with high CAT25 MSI exhibited a major peak of 64 bp in the 
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corresponding peripheral blood was 66 bp, demonstrating allelic instability. The HRM 
analysis identified correctly this tumour sample as abnormal. 
The immunohistochemistry (IHC) analysis was carried out in 9 of the 11 tumours with 
high MSI (Table 1). The PMS2 enzyme was absent in all samples and no expression 
of MLH1 was observed in 8/9, whereas MSH2 and MSH6 were expressed in all the 
tumours (Figure 3). All the cases analyzed by IHC correlated correctly with the 
results found in the microsatellite instability analysis (Table 1). 
 
Discussion  
MSI analysis is widely used in Lynch Syndrome screening, this being the most 
common cause of inherited colorectal cancer, accounting for 2%-4% of newly 
diagnosed cases and it is transmitted through an autosomal dominant pattern 
caused by germline mutations in the mismatch repair genes (23).  
The suggested replacement of the dinucleotide microsatellites from Bethesda 
panel for mononucleotides in the MSI analysis (7), promotes the study of new 
microsatellites associated with Lynch Syndrome. Our data suggest that CAT25 
appears as a very promising marker because it showed a limited allelic size variation 
in our population and besides, CAT25 could potentially give the same information 
alone as when used together with two additional markers from the Bethesda panel 
(BAT25 and BAT26). Moreover, CAT25 analysis can be carried out using a fast and 
simple technique such as HRM-PCR with certain advantages over capillary 
electrophoresis analysis, the most commonly used technique for MSI analysis.  
Eleven of 110 tumour samples (10%) had high MSI, in agreement with the 
range of 8 to 20% already reported in the literature (24).  Each of these high MSI 
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validated CAT25 HRM-PCR which also matched the results obtained with capillary 
electrophoresis analysis for CAT25. These findings together with the results from 
BAT25 and BAT26 in MSI testing from the same population reinforce the view that 
reducing the number of markers to be used from the Bethesda panel in the 
screening of Lynch Syndrome as proposed (4)(10)(11). Furthermore, fewer markers 
for MSI analysis provide the advantage of decreasing the costs and technical 
complexity while preserving the clinical applicability of the obtained results. CAT25 
alone demonstrated the same clinical utility as using CAT25 together with BAT25 
and BAT26 markers with optimal predictive values. Our findings are supported by 
previous literature using capillary electrophoresis analysis, where the sensitivity and 
specificity for microsatellite instability testing of CAT25 as a single marker were 
found to be the same as those detected when using five markers (BAT-25, BAT-26, 
MONO-27, NR-21, and NR-24) (25). However, it is known that HRM-PCR is faster 
and simpler than capillary electrophoresis and does not need post-PCR handling 
steps, therefore, reducing the harmful chance of contamination that can distort the 
results. 
CAT25 is a genetic marker that may vary in size depending on the patient 
ethnicity (10). Although the study of allelic size variation for CAT25 has been carried 
out previously for other populations (10), there were no reports of CAT25 analysis for 
a population like ours. In our study, we observed a limited range of repetitions in the 
microsatellite marker CAT25 from the healthy volunteers group. These data enable 
CAT25 to be introduced to a more inclusive microsatellite instability panel that 
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The CAT25 HRM-PCR validation was performed in the ECO, but the other platforms 
could also be used to obtain excellent performance defining CAT25 instability in 
tumours, reinforcing the robustness of the technique. Taking into account that the 
technical characteristics vary, greater resolution capacity could be obtained when 
using the Z480. This platform allows obtaining 25 reading acquisitions per °C in the 
HRM step in contrast to the 10 reading acquisitions per °C offered by ECO and RG, 
in addition to a more complete software platform to interpret the HRM results. IHC 
analysis customary for Lynch Syndrome found that MLH1 and PMS2 enzymes were 
absent while MSH2 and MSH6 were present in the tumours. The incorrect 
expression of the enzymes in the tumour tissue supports the lack of correction in the 
DNA replication errors, demonstrated by the shortening in the length of the 
microsatellites in the high MSI colorectal cancers. 
Although CAT25 HRM-PCR possess all the mentioned advantages, we have 
found three limitations for this technique: 1- lack of multiplex format, if this was to be 
implemented, it could become a more simple and high-throughput assay; 2- The 
need of PB DNA that contains the normal allele required to contrast with the tumour 
DNA, for HRM analysis; and lastly, 3- the arguable limited application of our CAT25 
HRM-PCR assay for paraffin-embedded tumour samples. The first two limitations are 
inherent to the HRM-PCR since it is an assay that is not characterized by easily 
adopting a multiplex format and usually a normal control is needed for the 
interpretation of its results, but they have the potential to be improved. On the third 
limitation, the validation of the assay for paraffin-embedded tissue will remain as a 
step to develop in the future. We believe all of these limitations can be solved 
through strategies such as those applied in analyzers like IdyllaTM MSI Assay 
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perform the study directly from paraffined-preserved tissue and does not require the 
analysis of paired normal tissue samples (26). However, the CAT25 analysis done 
by this new promising technology remains to be tested. 
A clear caveat with our data is the small number of samples with high MSI. 
Nevertheless, this work represents an advance in biomedical science because it 
provides pilot validation of an assay for CAT25 instability detection using PCR-HRM 




What is known about this subject: 
• MSI analysis is mainly used in Lynch Syndrome screening-management.  
 
• New mononucleotide microsatellites with limited size allelic variation are 
encouraged for the replacement of dinucleotides of the Bethesda panel. 
 
• CAT25 is a clinically effective MSI analysis (by capillary electrophoresis) in 
different ethnicities. 
 
What this paper adds: 
 
• CAT25 instability can be detected by a quick and simple technique such as 
PCR-HRM with certain advantages over capillary electrophoresis. 
 
• CAT25 has limited size allelic variation. 
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Table 1: Comparative results from Capillary electrophoresis, HRM curves and 
IHC analysis 
  
CE bp tumor (bp 
tumor - bp PB) 
HRM curves (tumor 
vs. PB) Immunohistochemistry   
Patient 
CAT2











































































































































































































































































           
 CE: capillary electrophoresis; HRM: high resolution melting; IHC: Immunohistochemistry; MSI: microsatellite instability; PB: 


















Figure 1: Variation of the amount of DNA template. From a range of 10 to 80 ng of DNA, 25 
ng/reaction were chosen to conduct our study. (A) Normalized and (B) Difference plots HRM curves of 
CAT25 marker from DNA of a tumour with instability in CAT25 (T109) and peripheral blood (S109) 
from the same patient; both replicated three times.  
Intra-assay reproducibility test for CAT25 marker. (C) Normalized and (D) Difference plots HRM 
curves from DNA of MSI(+) tumour vs. DNA from peripheral blood (PB) from the same patient; both 
replicated ten times. MSI(+): tumour with instability in CAT25 marker proved by capillary 



















Figure 2: Comparative analysis between capillary electrophoresis and HRM techniques. Capillary 
electrophoresis shows a -8 bp shift between DNA of tumour T102 (A) vs. DNA of peripheral blood 
(PB) S102 (B) from the same patient, denoting CAT25 instability. (C) and (D) Shifted allele in the cited 
samples reflected by normalized and difference plot HRM curves, respectively. HRM: high resolution 

















Figure 3: Immunohistochemical analysis. A- MLH1 40x, loss of nuclear MLH1 immunoreactivity in 
tumour tissue with immunoreactive lymphocyte infiltrate. B- MSH2 40x, positive nuclear 
immunoreactivity in tumour tissue. C- MSH6 10x, positive nuclear immunoreactivity in tumour tissue. 
D- PMS2 40x, Loss of nuclear PMS2 immunoreactivity in tumour tissue with immunoreactive 
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